National Bone Health Alliance Bone Turnover Marker Project: Current Practices and the Need for US Harmonization, Standardization, and Common Reference Ranges

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2012 Jul 17

PMID 22797491

Citations 62

Authors

D Bauer

J Krege

N Lane

E Leary

C Libanati

P Miller

G Myers

S Silverman

H W Vesper

D Lee

M Payette

S Randall

Affiliations

Soon will be listed here.

Abstract

Unlabelled: This position paper reviews how the National Bone Health Alliance (NBHA) will execute a project to help assure health professionals of the clinical utility of bone turnover markers; the current clinical approaches concerning osteoporosis and the status and use of bone turnover markers in the USA; the rationale for focusing this effort around two specific bone turnover markers; the need to standardize bone marker sample collection procedures, reference ranges, and bone turnover marker assays in clinical laboratories; and the importance of harmonization for future research of bone turnover markers.

Introduction: Osteoporosis is a major global health problem, with the prevalence and incidence of osteoporosis for at-risk populations estimated to be 44 million Americans. The potential of bone markers as an additional tool for health care professionals to improve patient outcomes and impact morbidity and mortality is crucial in providing better health care and addressing rising health care costs. This need to advance the field of bone turnover markers has been recognized by a number of organizations, including the International Osteoporosis Foundation (IOF), National Osteoporosis Foundation, International Federation of Clinical Chemistry, and Laboratory Medicine (IFCC), and the NBHA.

Methods: This position paper elucidates how this project will standardize bone turnover marker sample collection procedures in the USA, establish a USA reference range for one bone formation (serum procollagen type I N propeptide, s-PINP) and one bone resorption (serum C-terminal telopeptide of type I collagen, s-CTX) marker, and standardize bone turnover marker assays used in clinical laboratories. This effort will allow clinicians from the USA to have confidence in their use of bone turnover markers to help monitor osteoporosis treatment and assess future fracture risk. This project builds on the recommendations of the IOF/IFCC Bone Marker Standards Working Group by developing USA reference standards for s-PINP and s-CTX, the markers identified as most promising for use as reference markers.

Results: The goals of this project will be realized through the NBHA and will include its governmental, academic, for-profit, and non-profit sector stakeholders as well as major academic and commercial laboratories. Upon completion, a parallel effort will be pursued to make bone turnover marker measurements reliable and accepted by all health care professionals for facilitating treatment decisions and ultimately be reimbursed by all health insurance payers.

Conclusions: Successful completion of this project will help assure health professionals from the USA of the clinical utility of bone turnover markers and ties in with the parallel effort of the IOF/IFCC to develop worldwide bone turnover reference ranges.

Citing Articles

Anemia and Mineral Bone Disorder in Kidney Disease Patients: The Role of FGF-23 and Other Related Factors.

Carullo N, Sorbo D, Faga T, Pugliese S, Zicarelli M, Costa D Int J Mol Sci. 2024; 25(23).

PMID: 39684548 PMC: 11641783. DOI: 10.3390/ijms252312838.

Long-term second-generation antipsychotics decreases bone formation and resorption in male patients with schizophrenia.

Wang F, Li H, Yi K, Wu Y, Bian Q, Guo B Psychopharmacology (Berl). 2024; 241(9):1771-1780.

PMID: 38647696 DOI: 10.1007/s00213-024-06592-y.

A protocol for the prospective study of urinary cadmium with risk of fracture, bone loss, and muscle loss.

de la Bastide C, Soares L, Lui L, Harrington J, Cawthon P, Orwoll E JBMR Plus. 2024; 8(2):ziad006.

PMID: 38505523 PMC: 10945722. DOI: 10.1093/jbmrpl/ziad006.

Machine learning predicts the risk of osteoporosis in patients with breast cancer and healthy women.

Zhao F, Li C, Wang W, Zhang Y, Yao P, Wei X J Cancer Res Clin Oncol. 2024; 150(2):102.

PMID: 38393381 PMC: 10891247. DOI: 10.1007/s00432-024-05622-8.

Changes in Collagen Type I C-Telopeptide and Procollagen Type I N-Terminal Propeptide During the Menopause Transition.

Shieh A, Karlamangla A, Gossiel F, Eastell R, Greendale G J Clin Endocrinol Metab. 2023; 109(6):1580-1589.

PMID: 38087944 PMC: 11099485. DOI: 10.1210/clinem/dgad727.

References

Adami S, Bianchi G, Brandi M, Giannini S, Ortolani S, DiMunno O . Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int. 2008; 82(5):341-7. DOI: 10.1007/s00223-008-9126-5. View

Greenspan S, Parker R, Ferguson L, Rosen H, Karpf D . Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998; 13(9):1431-8. DOI: 10.1359/jbmr.1998.13.9.1431. View

Rogers A, Hannon R, Eastell R . Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res. 2000; 15(7):1398-404. DOI: 10.1359/jbmr.2000.15.7.1398. View

Ravn P, Hosking D, Thompson D, Cizza G, Wasnich R, McClung M . Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab. 1999; 84(7):2363-8. DOI: 10.1210/jcem.84.7.5847. View

Kim S, Park D, Park K, Kim S, Cho B, Lee H . Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J. 2006; 52(6):667-74. DOI: 10.1507/endocrj.52.667. View

Clowes J, Hannon R, Yap T, Hoyle N, Blumsohn A, Eastell R . Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone. 2002; 30(6):886-90. DOI: 10.1016/s8756-3282(02)00728-7. View

Christiansen C, Riis B, RODBRO P . Prediction of rapid bone loss in postmenopausal women. Lancet. 1987; 1(8542):1105-8. DOI: 10.1016/s0140-6736(87)91671-0. View

Linnet K . Two-stage transformation systems for normalization of reference distributions evaluated. Clin Chem. 1987; 33(3):381-6. View

Greenspan S, Resnick N, Parker R . Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled,.... J Clin Endocrinol Metab. 2005; 90(5):2762-7. DOI: 10.1210/jc.2004-1091. View

10.

Bauer D, Black D, Garnero P, Hochberg M, Ott S, Orloff J . Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004; 19(8):1250-8. DOI: 10.1359/JBMR.040512. View

11.

Rifai N, Cooper G, Brown W, Friedewald W, Havel R, Myers G . Clinical Chemistry journal has contributed to progress in lipid and lipoprotein testing for fifty years. Clin Chem. 2004; 50(10):1861-70. DOI: 10.1373/clinchem.2004.038976. View

12.

Keaveny T, Kopperdahl D, Melton 3rd L, Hoffmann P, Amin S, Riggs B . Age-dependence of femoral strength in white women and men. J Bone Miner Res. 2009; 25(5):994-1001. PMC: 3153366. DOI: 10.1359/jbmr.091033. View

13.

Cavalier E, Delanaye P . Defining a "reference population": no easy task. J Bone Miner Res. 2009; 24(9):1638. DOI: 10.1359/jbmr.090322. View

14.

Recker R, Stakkestad J, Chesnut 3rd C, Christiansen C, Skag A, Hoiseth A . Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone. 2004; 34(5):890-9. DOI: 10.1016/j.bone.2004.01.008. View

15.

Glover S, Garnero P, Naylor K, Rogers A, Eastell R . Establishing a reference range for bone turnover markers in young, healthy women. Bone. 2008; 42(4):623-30. DOI: 10.1016/j.bone.2007.12.218. View

16.

Rosen H, Moses A, Garber J, Iloputaife I, Ross D, Lee S . Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int. 2000; 66(2):100-3. DOI: 10.1007/pl00005830. View

17.

de Papp A, Bone H, Caulfield M, Kagan R, Buinewicz A, Chen E . A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone. 2007; 40(5):1222-30. DOI: 10.1016/j.bone.2007.01.008. View

18.

Ravn P, Clemmesen B, Christiansen C . Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone. 1999; 24(3):237-44. DOI: 10.1016/s8756-3282(98)00183-5. View

19.

Baim S, Miller P . Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res. 2009; 24(4):561-74. DOI: 10.1359/jbmr.090203. View

20.

Miller W, Myers G, Gantzer M, Kahn S, Schonbrunner E, Thienpont L . Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem. 2011; 57(8):1108-17. DOI: 10.1373/clinchem.2011.164012. View